Saeed Chashmniam1, Seyed Reza Mirhafez2,3, Maryam Dehabeh4, Mitra Hariri2,3, Mohsen Azimi Nezhad2,3,5, B Fatemeh Nobakht M Gh6,7. 1. Department of Chemistry, Sharif University of Technology, Tehran, Iran. 2. Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran. 3. Non-communicable Disease Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran. 4. Department of Biology, Payamnoor University, Mashhad, Iran. 5. Department of Medical Genetics, Mashhad University of Medical Sciences, Mashhad, Iran. 6. Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran. nobakhtf1@nums.ac.ir. 7. Non-communicable Disease Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran. nobakhtf1@nums.ac.ir.
Abstract
BACKGROUND/ OBJECTIVES: Curcumin, a natural polyphenol compound in the spice turmeric, has been found to have potent anti-oxidative and anti-inflammatory activity. Curcumin may treat non-alcoholic fatty liver disease (NAFLD) through its beneficial effects on biomarkers of oxidative stress (OS) and inflammation, which are considered as two feature of this disease. However, the effects of curcumin on NAFLD have been remained poorly understood. This investigation evaluated the effects of administrating curcumin on metabolic status in NAFLD patients. SUBJECTS/ METHODS: Fifty-eight NAFLD patients participated in a randomized, double-blind, placebo-controlled parallel design of study. The subjects were allocated randomly into two groups, which either received 250 mg phospholipid curcumin or placebo, one capsule per day for a period of 8 weeks. Fasting blood samples were taken from each subject at the start and end of the study period. Subsequently, metabolomics analysis was performed for serum samples using NMR. RESULTS: Compared with the placebo, supplementing phospholipid curcumin resulted in significant decreases in serum including 3- methyl-2-oxovaleric acid, 3-hydroxyisobutyrate, kynurenine, succinate, citrate, α-ketoglutarate, methylamine, trimethylamine, hippurate, indoxyl sulfate, chenodeoxycholic acid, taurocholic acid, and lithocholic acid. This profile of metabolic biomarkers could distinguish effectively NAFLD subjects who were treated with curcumin and placebo groups, achieving value of 0.99 for an area under receiver operating characteristic curve (AUC). CONCLUSIONS: Characterizing the serum metabolic profile of the patients with NAFLD at the end of the intervention using NMR-based metabolomics method indicated that the targets of curcumin treatment included some amino acids, TCA cycle, bile acids, and gut microbiota.
BACKGROUND/ OBJECTIVES: Curcumin, a natural polyphenol compound in the spice turmeric, has been found to have potent anti-oxidative and anti-inflammatory activity. Curcumin may treat non-alcoholic fatty liver disease (NAFLD) through its beneficial effects on biomarkers of oxidative stress (OS) and inflammation, which are considered as two feature of this disease. However, the effects of curcumin on NAFLD have been remained poorly understood. This investigation evaluated the effects of administrating curcumin on metabolic status in NAFLD patients. SUBJECTS/ METHODS: Fifty-eight NAFLD patients participated in a randomized, double-blind, placebo-controlled parallel design of study. The subjects were allocated randomly into two groups, which either received 250 mg phospholipid curcumin or placebo, one capsule per day for a period of 8 weeks. Fasting blood samples were taken from each subject at the start and end of the study period. Subsequently, metabolomics analysis was performed for serum samples using NMR. RESULTS: Compared with the placebo, supplementing phospholipid curcumin resulted in significant decreases in serum including 3- methyl-2-oxovaleric acid, 3-hydroxyisobutyrate, kynurenine, succinate, citrate, α-ketoglutarate, methylamine, trimethylamine, hippurate, indoxyl sulfate, chenodeoxycholic acid, taurocholic acid, and lithocholic acid. This profile of metabolic biomarkers could distinguish effectively NAFLD subjects who were treated with curcumin and placebo groups, achieving value of 0.99 for an area under receiver operating characteristic curve (AUC). CONCLUSIONS: Characterizing the serum metabolic profile of the patients with NAFLD at the end of the intervention using NMR-based metabolomics method indicated that the targets of curcumin treatment included some amino acids, TCA cycle, bile acids, and gut microbiota.
Authors: Keith D Lindor; Kris V Kowdley; E Jenny Heathcote; M Edwyn Harrison; Roberta Jorgensen; Paul Angulo; James F Lymp; Lawrence Burgart; Patrick Colin Journal: Hepatology Date: 2004-03 Impact factor: 17.425
Authors: Joel E Lavine; Jeffrey B Schwimmer; Mark L Van Natta; Jean P Molleston; Karen F Murray; Philip Rosenthal; Stephanie H Abrams; Ann O Scheimann; Arun J Sanyal; Naga Chalasani; James Tonascia; Aynur Ünalp; Jeanne M Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck Journal: JAMA Date: 2011-04-27 Impact factor: 56.272
Authors: Ailton Santos Sena Júnior; Felipe José Aidar; Jymmys Lopes Dos Santos; Charles Dos Santos Estevam; Jessica Denielle Matos Dos Santos; Ana Mara de Oliveira E Silva; Fábio Bessa Lima; Silvan Silva De Araújo; Anderson Carlos Marçal Journal: BMC Sports Sci Med Rehabil Date: 2020-08-06
Authors: Anna Pia Delli Bovi; Francesca Marciano; Claudia Mandato; Maria Anna Siano; Marcella Savoia; Pietro Vajro Journal: Front Med (Lausanne) Date: 2021-02-26